The extrapyramidal symptoms rating scale (ESRS) and its use in the evaluation of risperidone

Journal of Drug Development and Clinical Practice

Volumn 7, Issue 4, 1996, Pages 269-279

  Eberhard, G ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

ESRS; Extrapyromidal side effects; Risperidone

Indexed keywords

ANTIPARKINSON AGENT; BENZATROPINE; CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; PENFLURIDOL; RISPERIDONE; TRIHEXYPHENIDYL;

BASAL GANGLION; CLINICAL TRIAL; DRUG EFFICACY; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOTOR DYSFUNCTION; NONHUMAN; PARKINSONISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; RATING SCALE; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA;

EID: 0030024960     PISSN: 13579215     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Casey DE, Keepers GA. In: Casey DE, Christensen AV, editors. Psychopharmacology current trends, Berlin, Heidelberg, New York: Springer-Verlag, 1988:74-93.
2. Van Putten T. Arch Gen Psychiatry 1974;31:67-72.
3. Barnes TRE. J Psychopharmacol 1992;6:214-221.
4. Chouinard G, Ross-Chouinard A, Annable L.Jones BD. CanJ NeurologSci 19SO;7:1233.
5. Casey DE. Schizophr Res 1991:4:109-120.
6. PrattyJS, Q-rienJE, AnanthJ. AdvTher 1989;6:242-252.
7. Adler LA, Angrist B, Reiter S, Rotrosen J. Psychopharmacology 1989;97:1-11.
8. Barnes TRE. Psychiatr Dev 1987;4:301-319.
9. AydFJ.JAMA 1961;175:1054-1060.
10. Kane JM, Woemer M, Lieberman J. J Clin Psychopharmacol 1988;8:525-565.
11. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. J Clin Psychopharmacol 1988;8:215-265.
12. Chouinard G. In: Current approaches to schizophrenia. The 1st International Risperidone Investigators Meeting. Oxford: Oxford Clinical Communications, 1993:39-44.
13. Klawans HL, Rubovitz R. J Naval Transmission 1972;33:235-246.
14. Singh MM, Kay SR. J Nerv Mental Dis 1975;160:258-265.
15. Singh MM, Kay SR. Psychopharmacologia 1975;43:103-113.
16. Rivera-Calimlin L, Nasrallah H, Strauss J, et al. Am J Psychiatry 1976;133:646-652.
17. Gautier J, Jus A, Villeneuve A, et al. Biol Psychiatry 1977;12:389-399.
18. Chouinard G, Annable L, Cooper S. Comm Psychopharmacol 1977;1:325-331.
19. WojcikJ. Gelenberg A, La Brie RA, Mieske M. Comprehen Psychiatry 1980;21:370-379.
20. Simpson GM, Lee JH, Zoubok B, Gardos G. Psychopharmacol 1973;64:171-179.
21. Simpson GM, Angus JWS. Acta Psychiatr Scand 197U;212 Suppl 44:11-19.
22. Guy W. EC DEU Assessment manual for psycho-pharmacology. Rev. ed. Washington DC: US Department of Health, Education and Welfare, 1976.
23. Fleischhaker W, Bergmann KJ, Perovich R, et al. Psychopharmacol Bull 1989;25:222-226.
24. Mindham RHS. Br J Clin Pharmacol 1976; Suppl:395-400.
25. Chouinard G, Annable L, Ross-Chouinard A, Kropsky ML. J Clin Psychiatry 1979;40:147-152.
26. Chouinard G, Ross-Chouinard A, Gauthier S, et al [abstract]. 14th C1NP Congress, Florence, Italy, June 19-23,1984:16.
27. Wells BG, Cold JA, Marken PA, et al. J Clin Psychiatry 1991;52:255-260.
28. Filip V, Marsalek M, Halkova E, Karen R Psychiatry Res 1992;41:9-16.
29. Woolley DW, Shaw E. Proc Natl Acad Sei USA 1954;40:228-231.
30. Reyntjens AJM, Gelders YG, Hoppenbrouwers MLJA, Vanden Bussche G. Drug Dev Res 1986;8:205-211.
31. Ceulemans DLS, Gelders YG, Hoppenbrouwers ML, et al. Psychopharmacology 1985;85:329-332.
32. Leysen JE, Gommeren W, Eens A, et al. J Pharmacol Exp Ther 1988;247:661-670.
33. Meert TF, de Haes P, Janssen PAJ. Psychopharmacol 19S9;97:206-212.
34. Megens AAHP, Awouters FHL, Niemegeers CJE Psychopharmacol 198S;95:493-496.
35. Megens AAHP, Awouters FHL, Niemegeers CJE. Drug Dev Res 1989;17:23-33.
36. Megens AAHP, Niemegeers CJE, Awouters FHL. J Pharmacol Exp Ther 1992;260:160-167.
37. Heylen SLE, Gelders YG. In: Kane JM, editor. Risperidone: major progress in antipsychotic treatment. Oxford: Oxford Clinical Communications, 1991:27-30.
38. PeuskensJ. In: Johnstone EC, editor. Treatment of negative symptoms in schizophrenia. Oxford: Oxford Clinical Communications, 1990:32-44.
39. Marder SR, Meibach RC. Am J Psychiatry 1994;151:825-835.
40. Chouinard G.Jones B. Remington G, et al. J Clin Psychopharmacol 1993;13:25-40.
41. Heinrich K, Klieser E, Lehmann E, et al. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:129-137.
42. PeuskensJ and The Risperidone Study Group. Br J Psychiatry 1995:166:712-726.
43. Borison RL, Pathiroja AP, Diamond BJ, et al. Psychopharmacol Bull 1992:28:213-218.
44. Salier CF, Czupryna NJ, Salama AI. J Pharmacol Exp Ther 1990;253:1162-1170.